Brief: Cipla Enters JV With Kemwell Biopharma For Biologic Products
02/03/2026 15:24
March 2 (Reuters) - Cipla Ltd CIPL.NS: CIPLA - ENTERS 60:40 JOINT VENTURE WITH KEMWELL BIOPHARMA CIPLA - JOINT VENTURE TO DEVELOP AND COMMERCIALIZE BIOLOGIC PRODUCTS CIPLA - JV PARTNERS TO INVEST UP TO 100 MILLION RUPEES IN THEIR RESPECTIVE JV RATIO Source text: ID:nBSE90frGn Further company coverage: CIPL.NS ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cipla
See all newsFactbox: Global healthcare companies invest billions to boost US presence
Brief: Cipla, Qilu Pharmaceutical Partner For Licensing, Supply Of Biosimilar To Keytruda In US
India's Cipla, China's Qilu partner for US launch of Merck's Keytruda biosimilar
Brief: Cipla Enters Exclusive Partnership With Qilu For Keytruda Biosimilar In US
Brief: Cipla and SBP Group Sign Exclusive Licensing Agreement For HER2 Bispecific Antibody-Drug Conjugate